Selected research
Industry Growth & Trends
Global Metastatic Prostate Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Metastatic Prostate market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Metastatic Prostate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Metastatic Prostate is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Metastatic Prostate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Metastatic Prostate market include Genentech, BeiGene, Amgen, Zenith Epigenetics Ltd., VasGene Therapeutics, Inc., Telix Pharmaceuticals, SeleXel, Myovant Biosciences and Immunomedics(Gilead Sciences, Inc.), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Metastatic Prostate market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Metastatic Prostate market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Metastatic Prostate market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Metastatic Prostate.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Metastatic Prostate market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Metastatic Prostate Market by Company
Genentech
BeiGene
Amgen
Zenith Epigenetics Ltd.
VasGene Therapeutics, Inc.
Telix Pharmaceuticals
SeleXel
Myovant Biosciences
Immunomedics(Gilead Sciences, Inc.)
eFFECTOR Therapeutics
Arvinas Inc.
AB Science
Metastatic Prostate Segment by Type
Mono
Mono/Combination
Combination
Metastatic Prostate Segment by Application
Hospital
Drug Store
Online Pharmacy
Metastatic Prostate Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Prostate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Metastatic Prostate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Prostate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Metastatic Prostate companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Mono
- Mono/Combination
- Combination
Applications
- Hospital
- Drug Store
- Online Pharmacy
Companies covered
- Genentech
- BeiGene
- Amgen
- Zenith Epigenetics Ltd.
- VasGene Therapeutics, Inc.
- Telix Pharmaceuticals
- SeleXel
- Myovant Biosciences
- Immunomedics(Gilead Sciences, Inc.)
- eFFECTOR Therapeutics
- Arvinas Inc.
- AB Science
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Metastatic Prostate Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Metastatic Prostate Market Size by Region (2021-2032)
- 1.4.1 Global Metastatic Prostate Market Size by Region (2021-2026)
- 1.4.2 Global Metastatic Prostate Market Size by Region (2027-2032)
- 1.5 Key Regions Metastatic Prostate Market Size (2021-2032)
- 1.5.1 North America Metastatic Prostate Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Metastatic Prostate Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Metastatic Prostate Market Size Growth Rate (2021-2032)
- 1.5.4 South America Metastatic Prostate Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Metastatic Prostate Market Size Growth Rate (2021-2032)
2 Metastatic Prostate Market by Type
- 2.1 Type Introduction
- 2.1.1 Mono
- 2.1.2 Mono/Combination
- 2.1.3 Combination
- 2.2 Global Metastatic Prostate Market Size by Type
- 2.2.1 Global Metastatic Prostate Market Size Overview by Type (2021-2032)
- 2.2.2 Global Metastatic Prostate Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Metastatic Prostate Market Size Forecasted by Type (2027-2032)
- 2.3 Global Metastatic Prostate Market Size by Regions
- 2.3.1 North America Metastatic Prostate Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Metastatic Prostate Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Metastatic Prostate Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Metastatic Prostate Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Metastatic Prostate Market Size Breakdown by Type (2021-2026)
3 Metastatic Prostate Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Drug Store
- 3.1.3 Online Pharmacy
- 3.2 Global Metastatic Prostate Market Size by Application
- 3.2.1 Global Metastatic Prostate Market Size Overview by Application (2021-2032)
- 3.2.2 Global Metastatic Prostate Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Metastatic Prostate Market Size Forecasted by Application (2027-2032)
- 3.3 Global Metastatic Prostate Market Size by Regions
- 3.3.1 North America Metastatic Prostate Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Metastatic Prostate Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Metastatic Prostate Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Metastatic Prostate Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Metastatic Prostate Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Metastatic Prostate Industry Trends
- 4.2 Metastatic Prostate Industry Drivers
- 4.3 Metastatic Prostate Industry Opportunities and Challenges
- 4.4 Metastatic Prostate Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Metastatic Prostate Revenue (2021-2026)
- 5.2 Global Metastatic Prostate Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Metastatic Prostate Key Company Headquarters & Area Served
- 5.4 Global Metastatic Prostate Company, Product Type & Application
- 5.5 Global Metastatic Prostate Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Metastatic Prostate Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Metastatic Prostate Players Market Share by Revenue in 2025
- 5.6.3 2025 Metastatic Prostate Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Genentech
- 6.1.1 Genentech Company Information
- 6.1.2 Genentech Business Overview
- 6.1.3 Genentech Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Genentech Metastatic Prostate Product Portfolio
- 6.1.5 Genentech Recent Developments
- 6.2 BeiGene
- 6.2.1 BeiGene Company Information
- 6.2.2 BeiGene Business Overview
- 6.2.3 BeiGene Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 BeiGene Metastatic Prostate Product Portfolio
- 6.2.5 BeiGene Recent Developments
- 6.3 Amgen
- 6.3.1 Amgen Company Information
- 6.3.2 Amgen Business Overview
- 6.3.3 Amgen Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Amgen Metastatic Prostate Product Portfolio
- 6.3.5 Amgen Recent Developments
- 6.4 Zenith Epigenetics Ltd.
- 6.4.1 Zenith Epigenetics Ltd. Company Information
- 6.4.2 Zenith Epigenetics Ltd. Business Overview
- 6.4.3 Zenith Epigenetics Ltd. Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Zenith Epigenetics Ltd. Metastatic Prostate Product Portfolio
- 6.4.5 Zenith Epigenetics Ltd. Recent Developments
- 6.5 VasGene Therapeutics, Inc.
- 6.5.1 VasGene Therapeutics, Inc. Company Information
- 6.5.2 VasGene Therapeutics, Inc. Business Overview
- 6.5.3 VasGene Therapeutics, Inc. Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 VasGene Therapeutics, Inc. Metastatic Prostate Product Portfolio
- 6.5.5 VasGene Therapeutics, Inc. Recent Developments
- 6.6 Telix Pharmaceuticals
- 6.6.1 Telix Pharmaceuticals Company Information
- 6.6.2 Telix Pharmaceuticals Business Overview
- 6.6.3 Telix Pharmaceuticals Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Telix Pharmaceuticals Metastatic Prostate Product Portfolio
- 6.6.5 Telix Pharmaceuticals Recent Developments
- 6.7 SeleXel
- 6.7.1 SeleXel Company Information
- 6.7.2 SeleXel Business Overview
- 6.7.3 SeleXel Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 SeleXel Metastatic Prostate Product Portfolio
- 6.7.5 SeleXel Recent Developments
- 6.8 Myovant Biosciences
- 6.8.1 Myovant Biosciences Company Information
- 6.8.2 Myovant Biosciences Business Overview
- 6.8.3 Myovant Biosciences Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Myovant Biosciences Metastatic Prostate Product Portfolio
- 6.8.5 Myovant Biosciences Recent Developments
- 6.9 Immunomedics(Gilead Sciences, Inc.)
- 6.9.1 Immunomedics(Gilead Sciences, Inc.) Company Information
- 6.9.2 Immunomedics(Gilead Sciences, Inc.) Business Overview
- 6.9.3 Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Product Portfolio
- 6.9.5 Immunomedics(Gilead Sciences, Inc.) Recent Developments
- 6.10 eFFECTOR Therapeutics
- 6.10.1 eFFECTOR Therapeutics Company Information
- 6.10.2 eFFECTOR Therapeutics Business Overview
- 6.10.3 eFFECTOR Therapeutics Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 eFFECTOR Therapeutics Metastatic Prostate Product Portfolio
- 6.10.5 eFFECTOR Therapeutics Recent Developments
- 6.11 Arvinas Inc.
- 6.11.1 Arvinas Inc. Company Information
- 6.11.2 Arvinas Inc. Business Overview
- 6.11.3 Arvinas Inc. Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Arvinas Inc. Metastatic Prostate Product Portfolio
- 6.11.5 Arvinas Inc. Recent Developments
- 6.12 AB Science
- 6.12.1 AB Science Company Information
- 6.12.2 AB Science Business Overview
- 6.12.3 AB Science Metastatic Prostate Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 AB Science Metastatic Prostate Product Portfolio
- 6.12.5 AB Science Recent Developments
7 North America
- 7.1 North America Metastatic Prostate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Metastatic Prostate Market Size by Country (2021-2026)
- 7.3 North America Metastatic Prostate Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Metastatic Prostate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Metastatic Prostate Market Size by Country (2021-2026)
- 8.3 Europe Metastatic Prostate Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Metastatic Prostate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Metastatic Prostate Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Metastatic Prostate Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Metastatic Prostate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Metastatic Prostate Market Size by Country (2021-2026)
- 10.3 South America Metastatic Prostate Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Metastatic Prostate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Metastatic Prostate Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Metastatic Prostate Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst